Non-melanoma skin cancer (NMSC) is the most common cancer in the UK, with more than 155,000 cases of NMSC reported in the UK every year.1,2 However, NMSC is significantly under-r
Sanofi and Regeneron have built their case for Dupixent as a first biological therapy for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (AT
The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with San
Roche has made its case for BTK inhibitor fenebrutinib as a potential new oral therapy for multiple sclerosis, with a phase 2 readout that it says shows significant improv
Sanofi is already a big player in the Pompe disease market with injectable drugs like Nexviazyme and Myozyme/Lumizyme, but has now set its sights on an oral drug candidate